vecteezy_3d-virtual-tv-studio-news-backdrop-for-tv-shows-tv-on_3840500_9.jpg

News & Announcements

May 15, 2022

Irvine H.Page Junior Faculty Research Awarded to Oren Rom, PhD

 

April 13, 2022

"Induction of glutathione biosynthesis by glycine-based treatment mitigates atherosclerosis" (Redox Biology)

August 26, 2021

Patent JP-2021121626-A (Pending), Mixed disulfide conjugates of thienopyridine compounds and uses thereof (Japan)

 

March 25, 2021

Patent IL-280698-D0 (Pending), Tri-peptides and treatment of metabolic, cardiovascular and inflammatory disorders (Israel)

 

December 03, 2020

Amino Acid Connected to NAFLD Could Provide Treatment Clues

December 09, 2020

Patent EP-3746551-A1 (Pending), Biocatalyst and methods for synthesizing mixed disulfide conjugates of thienopyridine compounds (European Patent Office)

 

March 22, 2019

Patent NZ-719672-B2 (Pending), Tripeptide compositions and methods for treatment of diabetes (New Zealand)

 

April 11, 2018

Patent EP-2683393-B1 (Issued), Tripeptide compositions and their use for treatment of diabetes (European Patent Office)

 

March 15, 2018

Patent US-2018074053-A1 (Pending), Treatment of diabetes using agonists of the mas-related gpcr d (United States)

 

August 01, 2017

Diapin Therapeutics Announces Awarding of a Phase 1 NIH SBIR Grant for DT-678 Entitled "Novel ClopNPT for the treatment of acute coronary syndrome"


August 01, 2017

Patent US-9718778-B2 (Issued), Mixed disulfide conjugates of thienopyridine compounds and uses thereof (United States)

 

August, 30, 2016

Patent NZ-614080-B2 Published (Pending), Tripeptide compositions and methods for treatment of diabetes (New Zealand)

 

June 1, 2016

Patent CN105617351A (Issued), Peptide compositions and methods for treating patients (China)

 

December 01, 2015

Diapin Therapeutics Announces Awarding of a Phase 2 NIH SBIR Grant Entitled “Development of DT-110 as an oral therapeutic for type 2 diabetes"

August 28, 2015

Patent SG-11201505283R-A Published (Pending), Mixed disulfide conjugates of thienopyridine compounds and uses thereof (Singapore)

 

March 02, 2015

Diapin Therapeutics Announces Allowance of Claims from US Patent Application 14/087,247

February 01, 2015

Diapin Therapeutics Announces Awarding of a Phase 1 NIH SBIR Grant Entitled “Development of DT-109 as an Oral Therapeutic for Type 2 Diabetes"


November 18, 2014

Diapin Therapeutics Announces Signing of License Agreement with the University of Michigan for the Exclusive Rights to PCT/US2014/010348 entitled “Mixed Disulfide Conjugates of Thienopyridine Compounds and Uses Thereof"


March 25, 2014

Diapin Therapeutics Announces Issuance Receipt of the Patent from the U.S. Patent and Trademark Office

 

March 14, 2013

University of Michigan Spinout Diapin Therapeutics Attracts Chinese Investment by Sarah Schmid of Xconomy Detroit

 

September 15, 2011

University of Michigan and Diapin Therapeutics License Agreement by University of Michigan Board of Regents

 

December 30, 2011

Beijing Shuanglu Pharmaceutical to Invest in Diapin Therapeutics in Research in China